Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag for Secondary Prevention of Chemotherapy-induced Thrombocytopenia in Breast Cancer
NCT07647029Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jul 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
A Phase 2 trial of hetrombopag in chemotherapy-induced thrombocytopenia (CIT), sponsored by Fudan University. Started Jul 2026; status: recruiting.
02
Drugs
hetrombopag
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT07647029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647029.